May 07, 2018

EAS 2018 Lisbon, Portugal

May 05-08

Highlights from the second day of the Congress - May 06

Plenary session on "Cardiovascular health should be the priority"

Sunday’s Plenary session questioned whether the focus for cardiovascular prevention needs a rethink. In his lecture, Professor Valentin Fuster (Mount Sinai Heart, New York, USA) highlighted the need for renewed focus on promotion of cardiovascular health, based on primordial preventive approaches. Such an approach makes sense both from the individual and societal viewpoint, given that as atherosclerosis is a chronic disease, targeting intervention to individuals with cardiovascular disease – even subclinical – is already too late.

Also discussed in this session, by Professor Yusuf, beyond consideration of traditional cardiovascular risk factors –or ideal cardiovascular health – it is also important to take account of environmental determinants of risk, such as ambient air pollution, which even at levels below current standards, is significantly associated with increased risk of cardiovascular disease.

Read the full report from the Sunday plenary session >>

Breaking News on Lipoprotein(a):
How much should lipoprotein(a) be lowered for clinically relevant benefit?

That was the question posed at the First Late Breaking News Session of the Congress on Sunday May 06. Researchers led by Professor Brian A. Ference (Director of Research in Translational Therapeutics, the University of Cambridge, and Benjamin Meaker Visiting Professor, the University of Bristol, UK) provided important insights. These findings are highly pertinent given that phase three trials testing novel agents that have been shown to lower lipoprotein(a) by up to 90% by inhibiting apolipoprotein(a) synthesis are imminent.

Read the full report on this session >>

EAS 2018 Video interview: Professor Brian A. Ference on Lipoprotein (a)

Lipoprotein(a) has been a focus of news at EAS Congress Lisbon 2018. Professor Brian A. Ference (Director of Research in Translational Therapeutics, the University of Cambridge, and Benjamin Meaker Visiting Professor, the University of Bristol, UK) discusses the rationale, key findings and implications from a timely Mendelian randomization analysis which aimed to address the question: How much does lipoprotein(a) need to be lowered for a clinically relevant effect?

Watch the interview with Professor Ference >>

EAS 2018 Video interview: Dr. Arash Haghikia on Gut microbiota

The role of the gut microbiota is much in the news. At EAS Congress Lisbon 2018, Dr. Arash Haghikia, Department of Cardiology, Charité - Universitätsmedizin Berlin, Germany discusses recent findings from a study evaluating the potential for a metabolite derived from the gut microbiota, TMAO (trimethylamine-N-oxide), as a prognostic marker in secondary prevention.

Watch the interview with Dr. Haghikia >>


Follow the Congress in EAS news feed and social media channels
Videos and reports from the Congress are published on the Congress web: eas2018.com

Coming up a the Congress -

Wine & Science

Welcome to the Poster areas 17.00 on Monday May 07 for convivial poster viewing in our Wine & Science Sessions.

EAS Annual Members' General Assembly

On Monday May 07, starting at 17:00 in the Carolina Beatriz Àngelo - Auditorium 7, there will be a members-only General Assembly, to handle the Society's administrative & financial business.

Details about the session >>

Enjoy the Congress in Lisbon!

Find out more

About EAS

EAS Membership

EAS Congress

EAS Educational Initiatives

EAS Publications

European Lipoprotein Club (ELC)

EAS-FH Studies Collaboration (FHSC)

Visit: eas-society.org

About this email

You have received this email because you are currently subscribed to receive general correspondence from EAS.

  

European Atherosclerosis Society
Mässans Gata 18
Box 5243
SE-402 24, Gothenburg SWEDEN

Organisation number: 802418-0427

This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@

 

European Atherosclerosis Society © 2018